Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.63 +5.14%

+$0.45 today

Market cap
$53.90M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.01M

Average 0.05M

XLO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Xilio Therapeutics, Inc.NASDAQ: XLO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $2.21M rose 44.0% year over year, ahead of the +5.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 24.5% from the prior quarter. Over 3 fiscal years it compounded at -6.3% a year.

Context

  • Stock-based compensation amounted to 15.9% of revenue in FY2025, down 85.6 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +44.0% holds above the trailing-twelve-month pace of +5.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.21M-24.5% QoQ
Last fiscal yearDec 2025
$6.94M+7.8% YoY
LTMMar 2026
$6.49M+5.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+44.0%——
1 year+7.8%——
3-year CAGR-6.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
6.94M USD
Year-over-year change
+7.8%
4-year CAGR
+8.8%

Stock-Based Compensation vs competitors

How XLO compares with its peers on the latest reported figures

  • XLO's LTM Mar 2026 stock-based compensation of $6.49M is the 3rd largest of the 4 companies compared; the peer median is $237K.
  • Its year-over-year change of +5.8% is the 2nd highest of 4, against a peer median of -98.0%.
  • Stock-based compensation amounts to 12.1% of revenue for XLO, versus a peer median of 0.7%.
XLO Competitors Peer median
Stock-Based Compensation for XLO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PDSBPDS Biotechnology CorporationLTM Mar 2026$1.79B -27809.6%+824.6%—
OKUROnKure Therapeutics, Inc.LTM Mar 2026$11.67M +86.0%+523.5%—
XLOXilio Therapeutics, Inc.LTM Mar 2026$6.49M +5.8%-6.3%12.1%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$237K -98.0%+48.7%0.7%
Peer median (excluding XLO) $237K-98.0%+523.5%0.7%

Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Depreciation & Amortization1.5M1.85M1.9M1.64M1.54M
Deferred Income Tax222K0000
Stock-Based Compensation4.96M8.42M7.38M6.43M6.94M
Change in Working Capital(11.8M)2M(1.66M)31.78M25.13M
Accounts Receivables0000(5M)
Inventory00000
Accounts Payables(2.82M)485K(2.06M)1.53M152K
Other Working Capital(8.99M)1.52M405K30.26M29.97M
Other Non-Cash Items173K224K160K3K(3.56M)
Operating Cash Flow(80.75M)(75.72M)(68.62M)(18.38M)(4.99M)
Capital Expenditures(1.1M)(1.87M)(486K)(36K)(518K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(1.1M)(1.87M)(486K)(36K)(518K)
Debt Repayment(110K)(85K)(6.75M)(3.38M)0
Common Stock Issued116.36M16K202K6.83M87.78M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(467K)0025.75M0
Financing Cash Flow260.67M(69K)(6.55M)29.2M87.78M
Effect of Forex Changes0(9K)(25K)00
Net Change in Cash178.82M(77.67M)(75.68M)10.78M82.27M
Free Cash Flow(81.85M)(77.59M)(69.11M)(18.41M)(5.51M)

Xilio Therapeutics, Inc.

NASDAQ:XLO

Intrinsic Alpha fair value

Locked

Current Price

$7.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.